Compare Diamondback Energy Inc (FANG) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Diamondback Energy Inc vs TG Therapeutics Inc — how do they compare? Diamondback Energy Inc trades at $192.03 (market cap $53.67B), while TG Therapeutics Inc trades at $55.24 (market cap $8.16B). The key difference: Diamondback Energy Inc is far larger — about 6.6× TG Therapeutics Inc's market cap, and Diamondback Energy Inc pays a 2.3% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Diamondback Energy Inc for 69 Days and TG Therapeutics Inc for 16 Days on average.
| FANG | TGTX | |
|---|---|---|
Market Cap | $53.67B | $8.16B |
Volume | 2,250,644 | 1,735,121 |
Sector | Energy | Health |
52-Week High | $213.69 | $59.06 |
52-Week Low | $137.29 | $26.94 |
Typical Hold Time | 69 Days | 16 Days |
Enterprise Value | $65.83B | $8.37B |
Dividend Yield | 2.3% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Diamondback Energy (FANG) trades at $192.30, up 4.3% today, showing strong momentum near its recent highs. The stock maintains a bullish technical outlook with solid fundamental support from growing revenue and consistent earnings beats. Recent Q2 2026 EPS of $6.48 exceeded expectations by 6.6%, while analyst consensus remains overwhelmingly positive with 90.6% buy ratings and a $231.77 price target. The company's cash flow generation remains robust with $8.76B from operations in 2025, supporting dividend payments and strategic investments.
FANG presents a compelling growth opportunity with strong Permian Basin positioning and improving operational efficiency, though investors should monitor oil price volatility and recent insider selling activity. The stock's current valuation at 36.5x P/E reflects growth expectations, while technical indicators suggest potential resistance near $195-$197 levels. With solid institutional support and positive industry outlook, FANG remains well-positioned for continued upside if execution remains strong.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Diamondback Energy Inc
Diamondback Energy is an independent oil and gas producer in the United States. The company operates exclusively in the Permian Basin. At the end of 2021, the company reported net proven reserves of 1.8 billion barrels of oil equivalent. Net production averaged about 375,000 barrels per day in 2021, at a ratio of 60% oil, 20% natural gas liquids, and 20% natural gas.
Read more on FANG →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
